Vyant Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (loss) due to change in value of note payable	$ (5)	$ 13	$ (12)	$ (68)
VenturEast \| BioServe
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of shares associated with notes payable (in shares)			2,809		2,809
Gain (loss) due to change in value of note payable	5	(13)	$ 12	68
2016 Offering \| Significant Unobservable Inputs (Level 3) \| Fair Value Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain on derivative due to change in stock price	$ 34	$ 12	$ 233	$ 2,858